KBW analyst Christopher Mcgratty maintained a Buy rating on Banc of California (BANC – Research Report) today and set a price target of $20.00.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that its ...